Figure 3

CD30-mediated influence of galectin-1-mediated cell death and caspase inhibition. The vertical line represents the percentage of cell death. P-values were calculated by Student's t-test. Data represent an average±s.d. from two independent experiments. (a) Galectin-1-induced cell death was enhanced by CD30 pre-stimulation (Ki-1) of Karpas 299 cells (^*P=0.044604). (b) Galectin-1-induced cell death tended to be enhanced by CD30 pre-stimulation of DEL cells (P=0.06290). (c) CD30 pre-stimulation slightly induced cell death in JB6, galectin-1-induced cell death was not changed by CD30 stimulation (P=0.14758). (d–g) The galectin-1-induced cell death was not changed by CD30 pre-stimulation of L428 and L1236 cells ((d) L428, P=0.5, (e) L1236, P=0.452588) and tended to decrease in KMH2 and HDLM2 in combination with CD30 pre-stimulation ((f) KMH2, P=0.084490, (g) HDLM2, P=0.07125). But there is no statistically significant. NS: not significant. (h) Galectin-1-induced cell death was completely inhibited by the pan-caspase inhibitor z-VAD-fmk in Karpas 299 cells. Noteworthy, apoptosis of CD30/galectin-1-treated Karpas 299 cells was only partially inhibited by z-VAD-fmk. In all, 10–15% of cell death remained unaffected by caspase inhibition. One out of two experiments is shown.